ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Development and Validation of a Medication Safety Dashboard in Veteran Transplant Recipients: Preliminary Results of a Multicenter Cluster-Randomized Controlled Clinical Trial

D. Taber1, R. Felkner2, K. Rife3, D. Cooney3, S. Laforest3, E. Santa4, N. Super5, C. Hall6, T. Goddard1, R. Alexander1

1MUSC, Charleston, SC, 2Madison VA, Madison, WI, 3Cleveland VA, Cleveland, OH, 4Atlanta VA, Atlanta, GA, 5Chicago VA, Chicago, IL, 6Charleston VA, Charleston, SC

Meeting: 2022 American Transplant Congress

Abstract number: 150

Keywords: Drug interaction, HMG-CoA reductase inhibitor, Metabolic disease, Rejection

Topic: Clinical Science » Pharmacy » 30 - Non-Organ Specific: Clinical Pharmacy/Transplant Pharmacotherapy

Session Information

Session Name: Non-Organ Specific: Clinical Pharmacy/Transplant Pharmacotherapy

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:40pm-5:50pm

Location: Hynes Room 312

*Purpose: In organ transplant, med errors, adverse drug events, and nonadherence lead to increased healthcare utilization and graft loss. Veterans with transplants are a high-risk population.

*Methods: A med safety dashboard was created to identify potential issues that included missing pertinent labs, concerning trends in labs, drug-drug interactions, immunosuppressant non-adherence (refill gaps, expired meds), and transitions in care. This system was tested through a 24-month, prospective, cluster-randomized controlled multicenter study. Pharmacists at 5 intervention sites used the dashboard to identify and address potential med safety issues, which was compared with usual care provided at 5 control sites. Interim findings regarding dashboard functionality and interventions are reported here.

*Results: The study opened Mar 2019 and closed Jun 2021, with a COVID-19 induced hiatus (Apr to Jun 2020). As of the last interim analysis (18m follow-up), there were 1,928 patients enrolled across the 10 sites (1,181 intervention vs 815 control). Mean age was 65 years, 95% male, and 27% Black. Mortality was 9.3%, with no difference between arms (intervention 9.5% vs control 9.0%). ED visits (intervention 38.4% vs control 45.6%) and hospitalizations (intervention 25.6% vs control 37.6%) were higher in the control arm. The dashboard produced a total of 18,132 alerts from the 5 intervention sites; a rate of 1-2 per pt-month. Lab-based issues were most common (Figure 1), followed by non-adherence and transitions in care; 70% of alerts were addressed (Figure 2 blue bars) in about 40 days (Figure 2 orange line). Actions taken by pharmacists are displayed in Figure 3, which were often already addressed or not clinically relevant. Adjustments made to med regimens based on dashboard alerts were uncommon. Multivariable modeling demonstrated location site, type of alert, and transplant type were predictors of alerts being addressed (Table 1).

*Conclusions: This multicenter cluster-randomized controlled trial demonstrates that a med safety dashboard is feasibly deployable across the VA healthcare system, creating valid alerts; although most alerts were already addressed by other providers or deemed not to be clinically actionable. Future dashboard refinements should focus on reducing non-actionable alerts and addressing workload barriers to timely review.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Taber D, Felkner R, Rife K, Cooney D, Laforest S, Santa E, Super N, Hall C, Goddard T, Alexander R. Development and Validation of a Medication Safety Dashboard in Veteran Transplant Recipients: Preliminary Results of a Multicenter Cluster-Randomized Controlled Clinical Trial [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/development-and-validation-of-a-medication-safety-dashboard-in-veteran-transplant-recipients-preliminary-results-of-a-multicenter-cluster-randomized-controlled-clinical-trial/. Accessed May 29, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences